Real-time enrollment status for this stxbp1 encephalopathy clinical trial
Current Status
Suspended
Checked: March 2, 2026 at 12:06 PM UTC
| NCT Number | NCT06983158 |
| Recruiting Status | Suspended |
| Condition | STXBP1 Encephalopathy |
| Phase | Clinical Trial |
| Target Enrollment | 12 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Capsida Biotherapeutics, Inc. |
| Last Updated on CT.gov | October 1, 2025 (Oct 1, 2025) |
As of March 2, 2026: Clinical trial NCT06983158 is currently suspended participants. This clinical trial study for stxbp1 encephalopathy is not currently accepting new participants at 4 locations across the United States. The study is sponsored by Capsida Biotherapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
No, NCT06983158 is currently suspended. The study may resume recruiting in the future.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06983158 was last updated Oct 1, 2025 (October 1, 2025). HelloStudys verifies this status automatically.